{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T13:51:31Z","timestamp":1761918691551},"reference-count":32,"publisher":"Hindawi Limited","issue":"4","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":3816,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1111\/j.1368-5031.2005.00498.x","type":"journal-article","created":{"date-parts":[[2005,3,21]],"date-time":"2005-03-21T22:15:56Z","timestamp":1111443356000},"page":"485-495","source":"Crossref","is-referenced-by-count":41,"title":["Aripiprazole in schizophrenia: consensus guidelines"],"prefix":"10.1155","volume":"59","author":[{"given":"M. J.","family":"Travis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Burns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Dursun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Fahy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Frangou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. M.","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. M.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. H.","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","published-online":{"date-parts":[[2005,3,21]]},"reference":[{"key":"10.1111\/j.1368-5031.2005.00498.x-BIB1|cit1","unstructured":"National Institute for Clinical Excellence."},{"key":"10.1111\/j.1368-5031.2005.00498.x-BIB2|cit2","unstructured":"Otsuka Pharmaceuticals (UK) Ltd."},{"key":"10.1111\/j.1368-5031.2005.00498.x-BIB3|cit3","volume-title":"Aripiprazole - Summary","author":"Bristol-Myers Squibb Pharmaceuticals.","year":"2004"},{"key":"10.1111\/j.1368-5031.2005.00498.x-BIB4|cit4","unstructured":"Sanofi Synthelabo."},{"key":"10.1111\/j.1368-5031.2005.00498.x-BIB5|cit5","unstructured":""},{"key":"10.1111\/j.1368-5031.2005.00498.x-BIB6|cit6","unstructured":"Eli Lilly Ltd."},{"key":"10.1111\/j.1368-5031.2005.00498.x-BIB7|cit7","unstructured":"AstraZeneca UK Ltd."},{"key":"10.1111\/j.1368-5031.2005.00498.x-BIB8|cit8","unstructured":"AstraZeneca Pharmaceuticals LP."},{"key":"10.1111\/j.1368-5031.2005.00498.x-BIB9|cit9","unstructured":"Janssen-Cilag Ltd."},{"key":"10.1111\/j.1368-5031.2005.00498.x-BIB10|cit10","unstructured":"Pfizer."},{"key":"10.1111\/j.1368-5031.2005.00498.x-BIB11|cit11","unstructured":"Orion Pharma (UK) Ltd."},{"key":"10.1111\/j.1368-5031.2005.00498.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1017\/S1461145703003651","article-title":"Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia","volume":"6","author":"Kasper","year":"2003","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1111\/j.1368-5031.2005.00498.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/archpsyc.60.7.681","article-title":"Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder","volume":"60","author":"Potkin","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"10.1111\/j.1368-5031.2005.00498.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"763","DOI":"10.4088\/JCP.v63n0903","article-title":"Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder","volume":"63","author":"Kane","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"10.1111\/j.1368-5031.2005.00498.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.4088\/JCP.v64n0910","article-title":"Aripiprazole for the prevention of relapse in stabilised patients with chronic schizophrenia: a placebo-controlled 26-week study","volume":"64","author":"Pigott","year":"2003","journal-title":"J Clin Psychiatry"},{"issue":"Suppl.","key":"10.1111\/j.1368-5031.2005.00498.x-BIB16|cit16","first-page":"S157","article-title":"Aripiprazole: a novel antipsychotic: overview of a phase II study result","volume":"3","author":"Daniel","year":"2000","journal-title":"Int J Neuropsychopharmacol"},{"issue":"Suppl.","key":"10.1111\/j.1368-5031.2005.00498.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"S227","DOI":"10.1016\/S0924-977X(97)88746-9","article-title":"Aripiprazole, a new atypical antipsychotic: phase 2 clinical trial results","volume":"7","author":"Petrie","year":"1997","journal-title":"Eur Neuropsychopharmacol"},{"issue":"Suppl.","key":"10.1111\/j.1368-5031.2005.00498.x-BIB18|cit18","first-page":"S186","article-title":"Meta-analysis of the efficacy of aripiprazole in schizophrenia","volume":"5","author":"Lieberman","year":"2002","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1111\/j.1368-5031.2005.00498.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00213-002-1344-3","article-title":"Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study","volume":"166","author":"Casey","year":"2003","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1111\/j.1368-5031.2005.00498.x-BIB20|cit20","unstructured":"Tandon R Stock EG Kujawa MJ et al."},{"key":"10.1111\/j.1368-5031.2005.00498.x-BIB21|cit21","unstructured":"McQuade RD Jody DN Kukawa MJ et al."},{"key":"10.1111\/j.1368-5031.2005.00498.x-BIB22|cit22","unstructured":"Total Patient Tracker (TPT), Verispan, L.L.C., January 2003-June 2004."},{"key":"10.1111\/j.1368-5031.2005.00498.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0920-9964(03)00050-1","article-title":"Aripiprazole in the treatment of schizophrenia: safety and tolerability; in short-term, placebo-controlled trials","volume":"61","author":"Marder","year":"2003","journal-title":"Schizophr Res"},{"issue":"Suppl.","key":"10.1111\/j.1368-5031.2005.00498.x-BIB24|cit24","first-page":"S186","article-title":"Meta-analysis of weight effects with aripiprazole","volume":"5","author":"Jody","year":"2002","journal-title":"Int J Neuropsychopharmacol"},{"issue":"Suppl.","key":"10.1111\/j.1368-5031.2005.00498.x-BIB25|cit25","first-page":"S234","article-title":"Long-term weight effects of aripiprazole versus olanzapine in a 26-week double-blink study","volume":"7","author":"Kujawa","year":"2004","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1111\/j.1368-5031.2005.00498.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1192\/bjp.182.3.199","article-title":"Antipsychotic induced-hyperprolactinaemia in women: pathophysiology, severity and consequences","volume":"182","author":"Wieck","year":"2004","journal-title":"Br J Psychiatry"},{"issue":"Suppl.","key":"10.1111\/j.1368-5031.2005.00498.x-BIB27|cit27","first-page":"S186","article-title":"Meta-analysis of prolactin effects with aripiprazole","volume":"5","author":"Carson","year":"2002","journal-title":"Int J Neuropsychopharmacol"},{"issue":"Suppl.","key":"10.1111\/j.1368-5031.2005.00498.x-BIB28|cit28","first-page":"S186","article-title":"Meta-analysis of cardiac safety with aripiprazole","volume":"5","author":"Stock","year":"2002","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1111\/j.1368-5031.2005.00498.x-BIB29|cit29","unstructured":"Modell S Wilber R Marcus R et al."},{"key":"10.1111\/j.1368-5031.2005.00498.x-BIB30|cit30","unstructured":"Saha AR Brown D McEvoy J et al."},{"key":"10.1111\/j.1368-5031.2005.00498.x-BIB31|cit31","volume-title":"The Avon Mental Health Measure","author":"Markovitz","year":"1996"},{"key":"10.1111\/j.1368-5031.2005.00498.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1034\/j.1600-0447.2000.101006416.x","article-title":"Atypical antipsychotics and weight gain - a systematic review","volume":"101","author":"Taylor","year":"2000","journal-title":"Acta Psychiatr Scand"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1368-5031.2005.00498.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1368-5031.2005.00498.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T06:04:04Z","timestamp":1643349844000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1368-5031.2005.00498.x"}},"subtitle":["Aripiprazole in Schizophrenia"],"short-title":[],"issued":{"date-parts":[[2005,3,21]]},"references-count":32,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.1111\/j.1368-5031.2005.00498.x","relation":{},"ISSN":["1368-5031"],"issn-type":[{"value":"1368-5031","type":"print"}],"subject":[],"published":{"date-parts":[[2005,3,21]]}}}